Electronic Annex 5: Summary of adverse events reported per drug in the cohort of 658 cases of tuberculosis (TB) (adverse events are numerator and denominator)

Panel A: Overall summary of adverse events (n= 501^) reported by clinical centres per drug on 658 TB cases

	n* (%)	(95% Confidence Intervals)
Linezolid	92 (18.4)	15.0-21.8
Bedaquiline	79 (15.8)	12.6-19.0
Capreomycin	73 (14.6)	11.5-17.7
Pyrazinamide	57 (11.4)	8.6-14.2
Ethionamide/prothionamide	46 (9.2)	6.7-11.7
Amikacin	32 (6.4)	4.3-8.5
Cycloserine/terizidone	32 (6.4)	4.3-8.5
Para-aminosalicilic acid	29 (5.8)	3.8-7.9
Delamanid	18 (3.6)	2.0-5.2
Levofloxacin	16 (3.2)	1.7-4.7
Clofazimine	16 (3.2)	1.7-4.7
Moxifloxacin	10 (2.0)	0.8-3.2
Claritromycin	1 (0.2)	-0.2; 0.6

* adverse events per drug/total number of adverse events

^ in addition 3 patients with serious AEs attributed to all anti-TB drugs administered (2 gastrointestinal and 1 renal problem)

Panel B: Grade 1-2 (minor) adverse events (n=447) reported by clinical centres per drug on 658 TB cases

Grade 1-2 adverse events	n* (%)	(95% Confidence Intervals)
Linezolid	76 (17.0)	13.5-20.5
Capreomycin	68 (15.2)	11.9-18.5
Bedaquiline	73 (16.3)	12.9-19.7
Pyrazinamide	56 (12.5)	9.4-15.6
Ethionamide/prothionamide	45 (10.1)	7.3-12.9
Para-aminosalicilic acid	28 (6.3)	4.1-8.6
Amikacin	23 (5.1)	3.1-7.1
Cycloserine/terizidone	23 (5.1)	3.1-7.1
Delamanid	17 (3.8)	2.0-5.6
Levofloxacin	16 (3.6)	1.9-5.3
Clofazimine	13 (2.9)	1.3-4.5
Moxifloxacin	9 (2.0)	0.7-3.3
Claritromycin	0 (0.0)	-

* adverse events per drug/total number of adverse events

Panel C: Grade 3-5 (serious) adverse events **(**n=54^) reported by clinical centres per drug on 658 TB cases

Grade 3-5 adverse events	n* (%)	(95% Confidence Intervals)
Linezolid	16 (29.6)	17.4-41.8
Amikacin	9 (16.7)	6.8-26.6
Cycloserine/terizidone	9 (16.7)	6.8-26.6
Bedaquiline	6 (11.1)	2.7-19.5
Capreomycin	5 (9.3)	1.6-17.0
Clofazimine	3 (5.6)	-0.5; 11.7
Delamanid	1 (1.9)	-1.7; 5.5
Ethionamide/prothionamide	1 (1.9)	-1.7; 5.5

Moxifloxacin	1 (1.9)	-1.7; 5.5
Pyrazinamide	1 (1.9)	-1.7; 5.5
Claritromycin	1 (1.9)	-1.7; 5.5
Para-aminosalicilic acid	1 (1.9)	-1.7; 5.5
Levofloxacin	0 (0.0)	-

* adverse events per drug/total number of adverse events

^ in addition 3 AEs (2 gastrointestinal and 1 renal problem) attributed to all anti-TB drugs administered

Panel D: Overall summary of bedaquiline-related adverse events (n=79) reported by clinical centres on 658 TB cases

Bedaquiline, n* (%)	**n= 79**
Arrythmia	27 (34.2)
Pancreatitis	11 (13.9)
Hepatoxicity	9 (11.4)
Hypertransaminasemia	7 (8.9)
Renal failure	5 (6.3)
Nausea/vomiting	5 (6.3)
Arthromialgia	3 (3.8)
Peripheral neuropathy	3 (3.8)
Rash	3 (3.8)
Diarrhoea	2 (2.5)
Allergy	1 (1.3)
Anaemia	1 (1.3)
Gastritis	1 (1.3)
Other	1 (1.3)

* adverse event due to bedaquiline/total number of adverse events due to bedaquiline

Panel E: Overall summary of delamanid-related adverse events **(**n=18) reported by clinical centres on 658 TB cases

Delamanid, n* (%)	**n= 18**
Hypokalaemia	3 (16.7)
Arrythmia	2 (11.1)
Arthromyalgia	2 (11.1)
Rash	2 (11.1)
Hepatotoxicity	2 (11.1)
Anaemia	1 (5.6)
Nausea/vomiting	1 (5.6)
Candidosis	1 (5.6)
Depression	1 (5.6)
Eosinophilia	1 (5.6)
Gastritis	1 (5.6)
Headache	1 (5.6)

*adverse event due to delamanid/total number of adverse events due to delamanid

Panel F: Overall summary of linezolid-related adverse events (n=92) reported by clinical centres on 658 TB cases

Linezolid, n* (%)	**n= 92**
Peripheral neuropathy	37 (40.2)
Anaemia	24 (26.1)
Optic neuritis	5 (5.4)
Renal failure	5 (5.4)
Bone marrow suppression	3 (3.3)
Thrombocytopenia	3 (3.3)
Pancreatitis	2 (2.2)
Diarrhoea	2 (2.2)
Hypokalaemia	2 (2.2)
Nausea/vomiting	2 (2.2)
Candidiasis	1 (1.1)
Epistaxis	1 (1.1)
Hearing problems	1 (1.1)
Hepatotoxicity	1 (1.1)
Increased foetal movement	1 (1.1)
Increased lactate levels	1 (1.1)
Rash	1 (1.1)

* adverse event due to linezolid/total number of adverse events due to linezolid

Panel G: Overall summary of capreomycin-related adverse events (n=73) reported by clinical centres on 658 TB cases

Capreomycin, n* (%)	**n= 73**
Renal failure	20 (27.4)
Eosinophilia	16 (21.9)
Hearing problems	12 (16.4)
Hypokalaemia	10 (13.7)
Allergy	10 (13.7)
Increased blood creatinine	2 (2.7)
Diarrhoea	1 (1.4)
Headache	1 (1.4)
Peripheral neuropathy	1 (1.4)

* adverse event due to capreomycin/total number of adverse events due to capreomycin

Panel H: Overall summary of pyrazinamide-related adverse events (n=57) reported by clinical centres on 658 TB cases

Pyrazinamide, n* (%)	**n= 57**
Hyperuricemia	12 (21.1)
Arthromyalgia	11 (19.3)
Renal failure	7 (12.3)
Allergy	6 (10.5)
Eosinophilia	5 (8.8)
Hypertransaminasemia	4 (7.0)
Nausea/vomiting	3 (5.3)
Hepatotoxicity	3 (5.3)
Itching	2 (3.5)
Diarrhoea	2 (3.5)
Gastritis	2 (3.5)

* adverse event due to pyrazinamide/total number of adverse events due to pyrazinamide